How has the development of new therapies affected the treatment of Crohn disease?

Updated: Jul 26, 2019
  • Author: Leyla J Ghazi, MD; Chief Editor: Praveen K Roy, MD, AGAF  more...
  • Print

Treatment of Crohn disease has changed over the past few years, reflecting new therapies that can target specific locations in the gastrointestinal (GI) tract and specific cytokines. The development of biologic anti–tumor necrosis factor (anti-TNF) agents (eg, infliximab, adalimumab, certolizumab pegol, and natalizumab) has significantly advanced the treatment of Crohn disease and improved the induction and maintenance of clinical remission in patients with moderate to severe disease, especially in those who are corticosteroid dependent. [84]  Anti-TNF agents are effective for induction and maintenance of remission in patients with Crohn disease and active inflammation. [12]

Antibiotics can decrease anal fistula discharge and may induce remission in Crohn disease. [12]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!